PTMA gene is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-16. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Peptide | 28 amino acid residues |
| Molecular weight | Approximately 3108 Da | Depends on acetylation state |
| N-terminal modification | Acetylated | Affects charge and stability |
| Natural source | Fragment of thymosin beta-4 | Cleaved in vivo |
| Sequence length | 28 residues | Synthetic form matches natural |
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
In a study published in 2010, researchers from Peking University studying ultrasound images of infants who fell ill in the 2008 contamination found while most children in a rural Chinese area recovered, 12 per cent still showed kidney abnormalities six months later. "The potential for long-term complications after exposure to melamine remains a serious concern", the report said. "Our results suggest a need for further follow-up of affected children to evaluate the possible long-term impact on health, including renal function."
=== Binding === DCBQ is an electrophilic compound, so it can bind in the human body to multiple nucleophilic compounds. DCBQ can, for instance, react with GSH, substituting the Cl groups for the GS group. DCBQ is thus being dechlorinated and can undergo Michael addition with GSH, resulting in more glutathionylated products. The second Cl group can also be removed from the compound when reacting with another GSH molecule. DCBQ can also undergo redox reactions when reacting with an electron, forming radicals. These radicals can also react with GSH, forming more conjugation products. DCBQ can also react with amino acids. When DCBQ was brought in contact with amino acids, the DCBQ was quickly removed, suggesting that the DCBQ reacted with the amino acids. DCBQ binds to the DNA via H-bonds, a non-covalent interaction. Because of its hydrophobicity, DCBQ might be intercalated between nucleotides in a double-stranded DNA molecule [source]. This intercalation might lead to increased access to the nucleotides, possibly leading to even more oxidative damage in the DNA. Amino acids can also covalently bind to DCBQ. The amino acids undergo nucleophilic substitution with both DCBQ and DCBQ-OH, the product of DCBQ hydrolysis. Proteins can be bound by DCBQ covalently via cysteine or lysine residues. Catechins, which are naturally present in for instance green tea, can competitively bind to DCBQ, reducing the amount of proteins bound to DCBQ [16]. The proteins are covalently modified when bound to DCBQ, which might change the stability and alter the function of the protein.
Tryptophan (symbol Trp or W), historically also known as tryptophane, is an α-amino acid that is used in the biosynthesis of proteins. Tryptophan contains an α-amino group, an α-carboxylic acid group, and a side chain indole, making it a polar molecule with a non-polar aromatic beta carbon substituent. Tryptophan is also a precursor to the neurotransmitter serotonin, the hormone melatonin, and vitamin B3 (niacin). It is encoded by the codon UGG. Like other amino acids, tryptophan is a zwitterion at physiological pH where the amino group is protonated (–NH+3; pKa = 9.39) and the carboxylic acid is deprotonated (–COO−; pKa = 2.38). Humans and many animals cannot synthesize tryptophan; they need to obtain it through their diet, making it an essential amino acid. Tryptophan is named after the digestive enzymes trypsin, which were used in its first isolation from casein proteins. It was assigned the one-letter symbol W based on the double ring being visually suggestive to the bulky letter.
Archimedes reportedly exclaimed "Eureka" after he realized how to detect whether a crown is made of impure gold. While he did not use Archimedes' principle in the widespread tale and used displaced water only for measuring the volume of the crown, there is an alternative approach using the principle: Balance the crown and pure gold on a scale in the air and then put the scale into water. According to Archimedes' principle, if the density of the crown differs from the density of pure gold, the scale will get out of balance under water.
=== Debate over Mercury project continuation === The Mercury-Atlas 8 flight of Walter Schirra on October 3, 1962, had been so nearly perfect that some at NASA thought that the United States should quit while it was ahead and make MA-8 the last Mercury mission rather than risk a future disaster. The argument that MA-8 should be the last Mercury mission held that NASA had pushed the first-generation Mercury hardware far enough, and taking more chances on another longer mission was not warranted; instead, NASA should move on to the Gemini program. Manned Spacecraft Center officials, however, believed that the Mercury team should be given the chance to test a human in space for a full day. In addition, all of the Soviet single-seat Vostok spacecraft launched after Vostok 1 lasted for more than a day; thus the Mercury 9 flight would bring the Mercury spacecraft up to the same level as that of the Soviets.
Sources: en.wikipedia.org
Nickel ores are classified as oxides or sulfides. Oxides include laterite, where the principal mineral mixtures are nickeliferous limonite, (Fe,Ni)O(OH), and garnierite (a mixture of various hydrous nickel and nickel-rich silicates). Nickel sulfides commonly exist as solid solutions with iron in minerals such as pentlandite and pyrrhotite with the formula Fe9\−xNixS8 and Fe7\−xNixS6, respectively. Other common Ni-containing minerals are millerite and the arsenide niccolite. Identified land-based resources throughout the world averaging 1% nickel or greater comprise at least 130 million tons of nickel (about the double of known reserves). About 60% is in laterites and 40% in sulfide deposits. On geophysical evidence, most of the nickel on Earth is believed to be in Earth's outer and inner cores. Kamacite and taenite are naturally occurring alloys of iron and nickel. For kamacite, the alloy is usually in the proportion of 90:10 to 95:5, though impurities (such as cobalt or carbon) may be present. Taenite is 20% to 65% nickel. Kamacite and taenite are also found in nickel iron meteorites. Nickel is commonly found in iron meteorites as the alloys kamacite and taenite. Nickel in meteorites was first detected in 1799 by Joseph-Louis Proust, a French chemist who then worked in Spain. Proust analyzed samples of the meteorite from Campo del Cielo (Argentina), which had been obtained in 1783 by Miguel Rubín de Celis, discovering the presence in them of nickel (about 10%) along with iron.
The player must explore others houses and buildings around the map to find food and water to avoid starving and dehydrating, which will end the game (if on permadeath mode; otherwise, they will respawn back at the last hatch they visited.) The Night Watch mode focuses on the game's combat features and instead of being a downer, the player plays as a Bobby named John Constable (or "Constable Constable" for short). The player spawns on a randomly generated island in the Village of Hamlyn, with no bridges leading off of the island. The mode is round-based, and to advance the rounds, the player must eliminate all enemies that spawn in until the rounds timer ends, in which the player can use a Bobby Popper to end the round. The player earns money (pounds) by eliminating enemies, consisting of Downers, "Headboys", Plaguies, and Wastrels. Witches can spawn, serving as mini-bosses and dealing the most damage out of any enemy, but also give major rewards when defeated. As well as spending their money on vending machines to gain better gear and items, players must spend their money on Joy, which they need to do regularly as their Joy Meter goes down. If the player character run out of Joy, the game ends. Joy starts at £20, but the price goes up every round. The player always takes Blackberry Flavour of Joy, a rarer version of the drug exclusively made for the Bobbies. As the player defeats enemies, their Rage Meter grows, with one slot of it being filled per elimination.
== Early life == Nayib Armando Bukele Ortez was born on 24 July 1981 in San Salvador, El Salvador. His father was Armando Bukele Kattán, a businessman and industrial chemist, and his mother is Olga Marina Ortez. Bukele's father died in 2015. Bukele was the couple's first child. He has three younger brothers, Karim, Yusef, and Ibrajim, and has four paternal half-sisters and two paternal half-brothers. Bukele's father converted from Christianity to Islam in the 1980s, became an imam, and founded four mosques in El Salvador. Bukele's mother is Catholic. Bukele's paternal grandparents were Palestinian Christians who emigrated to El Salvador from Jerusalem and Bethlehem in 1921. His maternal grandfather was Greek Orthodox, and his maternal grandmother was Catholic. Bukele completed his secondary education at the Escuela Panamericana in 1999 at age 18. Bukele enrolled at Central American University in San Salvador to study legal sciences, aspiring to become a lawyer, but dropped out to work for the Nölck advertising agency, one of his father's businesses. Nölck campaigned for the Farabundo Martí National Liberation Front (FMLN), a left-wing Salvadoran political party. In 1999, Bukele founded the marketing company Obermet, also known as 4am Saatchi & Saatchi El Salvador, and was its president from 1999 to 2006 and from 2010 to 2012. The company ran political advertising for the FMLN presidential campaigns of Schafik Hándal in 2004 and Mauricio Funes in 2009.
April 1 Trump says US military action in Iran could end in "two to three weeks", and that the US will "leave whether we have a deal or not" once he's certain Iran cannot build a nuclear weapon "for years". NASA launches the Artemis II lunar flyby mission from the Kennedy Space Center in Florida, the first crewed flight beyond low Earth orbit since Apollo 17 in 1972. With a crew of four astronauts – Reid Wiseman (commander) Victor Glover (pilot), Christina Koch (mission specialist), and Canadian astronaut Jeremy Hansen (mission specialist) – it also becomes the first time a person of color, a woman, and a non-United States citizen have left low Earth orbit. The Supreme Court hears oral arguments over the constitutionality of Trump's Executive Order 14160 ending birthright citizenship. Trump is in attendance, a first for a sitting president. The DOJ publishes an opinion that the Presidential Records Act is an unconstitutional overreach of congressional power, and advises Trump that he can refuse to hand over records to the National Archives and Records Administration at the end of his term. April 2 Trump fires Attorney General Pam Bondi, who is replaced by Todd Blanche in an acting capacity. Defense Secretary Hegseth fires three high-ranking U.S. Army generals: Chief Staff Randy George, Chief of Chaplins William Green Jr., and T2COM Commander David Hodne. The Pentagon did not provide a reason. The Colorado Court of Appeals vacates the nine-year sentence of 2020 election denier Tina Peters on First Amendment free speech grounds and remands the case for resentencing.
Sources: en.wikipedia.org
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.
It is usually described as an immunomodulatory peptide rather than a classical hormone. It does not travel to a single distant organ in the manner of an endocrine hormone. Classification varies across sources, and some texts group it with thymic peptides generally.
The broad outline involves immune cell activation, but the specific molecular steps remain under investigation. Different studies report effects on dendritic cells, T cells, and natural killer cells. No single receptor has been confirmed as the sole mediator.
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.